Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure

Project Title Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure
Date Posted
Wednesday, August 26, 2020
Project ID
cder_mpl1p_wp036, cder_mpl1r_wp169
Status
Complete
Deliverables
Related Links
Description

In this analysis we examined counts of new users of sacubitril/valsartan, angiotensin-converting enzyme (ACE) inhibitors, and other angiotensin II receptor blockers (ARBs) with heart failure in the Sentinel Distributed Database (SDD). We also captured switching between products.

This analysis include two reports containing data from 16 Data Partners contributing to the SDD. Data from January 1, 2015 to July 31, 2019 were included in Report 1, which was distributed on December 6, 2019. Data from January 1, 2015 to July 31, 2019 were included in Report 2, which was distributed on February 27, 2020.

Medical Product
angiotensin II receptor blocker (ARB)
angiotensin-converting enzyme (ACE) inhibitor
sacubitril/valsartan
Population / Cohort
Individuals 18 years of age and older
Time Period
January 1, 2015 - July 31, 2019
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER
Scroll to Top